Trial · NCT07310069
Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer
NCT07310069, Phase 2, Enrolling by invitation, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer. Trials, record NCT07310069. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07310069
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer
- NCT number
- NCT07310069
- Status
- Enrolling by invitation
- Phases
- Phase 2
- Enrollment
- 44 participants, estimated
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Conditions
- Gallbladder Cancer Unresectable
- Interventions
- Treatment :Gemcitabine plus Nab-Paclitaxel (AG regimen) in combination with Iparomlimab and Tuvorili
- First posted
- 2025-12-30
- Last updated
- 2025-12-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR | At the end of Cycle 6 (each cycle is 21 days) | The objective response rate (ORR) of this quadruplet regimen as first-line therapy |
| Primary | Surgical Conversion Rate | At the end of Cycle 6 (each cycle is 21 days) | Proportion of patients who achieve successful conversion to radical resection (R0/R1) after systemic therapy. |
| Secondary | Downstaging Rate | At the end of Cycle 6 (each cycle is 21 days) | Proportion of patients whose clinical stage is reduced after conversion therapy. |
| Secondary | Pathologic Response Rate | At the end of Cycle 6 (each cycle is 21 days) | Proportion of patients with pathologic downstaging or major pathologic response in resected specimens |
| Secondary | R0 Resection Rate | At the end of Cycle 6 (each cycle is 21 days) | Proportion of patients who undergo R0 resection among those who receive surgery. |
| Secondary | Disease Control Rate (DCR) | At the end of Cycle 6 (each cycle is 21 days) | Proportion of patients with CR, PR, or stable disease (SD) lasting ≥4 weeks. |
| Secondary | Recurrence-Free Survival (RFS) | up to 2 years | Proportion of patients without recurrence at 2 years after resection. |
| Secondary | Overall Survival (OS) | through study completion,up to 3 years | Time from enrollment to death from any cause. |
| Secondary | Adverse Events (AEs) / Serious AEs (SAEs) | through study completion, up to 30 days | Incidence and severity of AEs and SAEs graded by CTCAE v5.0. |
| Secondary | Surgical Safety | Perioperative | Incidence of surgery-related complications (e.g., infection, bleeding, organ dysfunction) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07310069
GET https://conductscience.org/api/trials/v1/NCT07310069/registered